PrintThe Burrill Report (December 9, 2013): Pharma Faces Shrinking Returns from Innovation(.MP3,15.87 Mb)
The biggest pharmaceutical companies are successfully bringing new products to market, but are struggling with diminishing returns on investment, according to a new report from Deloitte and Thomson Reuters. We spoke to Neil Lesser, principal of life sciences strategy for Deloitte, about the industry’s efforts to remake R&D, why the value of innovation seems to be falling, and what successful companies are doing to drive value from their R&D operations.December 05, 2013
http://www.burrillreport.com/article-pharma_faces_shrinking_returns_from_innovation.html
